Considering that the PD-L1/PD-1 axis constitutes a major therapeutic target in solid tumors and hematologic malignancies, our data provide significant insights into therapy resistance mechanisms and the development of immune adverse events. This evidence concerns the gene CD274 and hematologic disorder.